|
|||
 |
|||
|
Etanercept - Enbrel controls your body's defensive response by blocking the action of a certain natural substance (TNF) that is used by the immune system. Treatment decreases redness, itching and scaly patches in psoriasis as well as the pain, swelling and stiffness of joints in arthritis. This medication can stop the progression of disease and joint damage, resulting in improved daily functioning and quality of life. The Psoriasis randomized Etanercept study results demonstrated that Enbrel 50 mg once-weekly or twice-weekly provides improvement of skin symptoms which continue to improve over time. In particular: * At only 12 weeks, over half (55%) of patients taking Enbrel 50mg twice-weekly and more than one third (36%) of patients taking Enbrel 50 mg once-weekly showed a 75% improvement in the psoriasis area-and-severity index (PASI 75) * After 24 weeks, over two thirds (70%) of patients taking Enbrel (50 mg twice-weekly for 12 weeks, followed by 50 mg once-weekly for 12 weeks) showed a 75% improvement in the psoriasis area-and-severity index (PASI 75), demonstrating that skin clearance continues to improve with Enbrel, even after Enbrel's dose is reduced * Almost two thirds (62%) of patients treated throughout with 50 mg once-weekly also went on to achieve PASI 75 by week 24 * In addition, approximately three out of four patients (72-77%) taking Enbrel showed joint improvement, as measured by the Psoriatic Arthritis Response Criteria (PsARC), at only 12-weeks and maintained this improvement at 24-weeks Previous research has shown that the skin symptoms in psoriasis patients are associated with a low quality of life comparable to, or even worse than those individuals with other chronic medical disorders, including heart disease. Further results from the Psoriasis randomized Etanercept study presented today demonstrate that Enbrel not only clears skin, but can also improve patients' quality of life. |
|||
|
|||
|
|||
|
|||
|
